Gland Pharma Ltd announces conclusion of US FDA Inspection at VSEZ Sterile Oncology Facility, Visakhapatnam

The United States Food and Drug Administration (US FDA) has conducted Good Manufacturing Practice (GMP) Inspection at the Company's VSEZ Sterile Oncology Facility at Visakhapatnam between 20th July, 2023 and 28th July, 2023.

The inspection was concluded with Zero 483 observations and a classification of No Action Indicated (NAI).

Shares of Gland Pharma Limited was last trading in BSE at Rs. 1294.00 as compared to the previous close of Rs. 1267.15. The total number of shares traded during the day was 62699 in over 5703 trades.

The stock hit an intraday high of Rs. 1300.00 and intraday low of 1251.15. The net turnover during the day was Rs. 80772550.00.

Source : Equity Bulls

Keywords

GlandPharma INE068V01023 USFDA GMPInspection VSEZ SterileOncologyFacility